U.S. Markets closed

Genmab A/S (GEN.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
1,427.00-4.00 (-0.28%)
At close: 4:59PM CEST
Full screen
Previous Close1,431.00
Bid1,425.00 x 0
Ask1,426.00 x 0
Day's Range1,422.00 - 1,448.00
52 Week Range1,041.00 - 1,489.00
Avg. Volume210,742
Market Cap87.25B
PE Ratio (TTM)65.30
EPS (TTM)21.85
Earnings DateNov 8, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,515.31
  • Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors
    Business Wire22 days ago

    Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors

    Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development.

  • Reuters27 days ago

    Cyclicals boost European shares while Dixons Carphone plummets

    Gains by cyclical sectors helped push European stocks higher on Thursday while heavy losses in Dixons Carphone after a profit warning dominated trading. Dixons Carphone shares plummeted as much as 29 percent after the mobile phone retailer downgraded expectations for full-year profit, reflecting tougher conditions in the mobile market as customers hold on to handsets for longer. "With the December results some way off and Black Friday week (of retail discounts) looming, Dixons will be under pressure to provide additional detail on today's complex variables in coming weeks," said Stifel analysts.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of GEN.CO earnings conference call or presentation 9-Aug-17 4:00pm GMT

    Q2 2017 Genmab A/S Earnings Call